This early phase I trial studies how well fingolimod works in treating patients with
chemotherapy-induced nerve pain (neuropathy). Fingolimod acts by suppressing immune reactions
in the brain. This study is being done to see if fingolimod can reduce neuropathy caused by
I. To evaluate whether fingolimod markedly improves symptoms in patients with established
(chemotherapy-induced peripheral neuropathy) CIPN.
II. To evaluate the tolerability of fingolimod in these treated patients.
Patients receive fingolimod orally (PO) once daily (QD) for 4 weeks.
After completion of study treatment, patients are followed up every month for 3 months.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.